Expert Review of Hematology最新文献_第4页

Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia. 将心血管风险评估纳入慢性淋巴细胞白血病BTK抑制剂的常规管理。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-09-01 Epub Date: 2026-07-06 DOI: 10.1080/17474086.2026.2699804

Stefano Molica, Stefano Oliva, Giuliana Farina, Roberta Esposito

{"title":"Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia.","authors":"Stefano Molica, Stefano Oliva, Giuliana Farina, Roberta Esposito","doi":"10.1080/17474086.2026.2699804","DOIUrl":"10.1080/17474086.2026.2699804","url":null,"abstract":"Introduction: Cardiovascular (CV) toxicities remain a major challenge during Bruton tyrosine kinase inhibitor (BTKi) therapy for chronic lymphocytic leukemia (CLL). Selecting the optimal BTKi based solely on a history of overt CV disease may underestimate underlying cardiovascular vulnerability.Areas covered: We performed a targeted, non-systematic review of PubMed and MEDLINE to examine the association between baseline CV comorbidities and BTKi-related CV toxicities in CLL. Current evidence indicates that preferential use of BTKis with more favorable CV safety profiles, coupled with appropriate cardio-oncology surveillance, reduces the risk of CV adverse events in patients with pre-existing CV disease. In patients without established CV disease, the Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons (SCORE2-OP) may help identify clinically meaningful latent CV risk, enabling early optimization of modifiable risk factors in line with the proactive cardiovascular management strategy endorsed by the 2026 European Hematology Association (EHA) CLL guidelines.Expert opinion: A structured, risk-adapted approach integrating standardized CV risk assessment, early management of modifiable risk factors, individualized BTKi selection, and multidisciplinary cardio-oncology collaboration may improve the safety and tolerability of BTKi therapy in CLL. Pending prospective validation, SCORE2 and SCORE2-OP should complement, rather than replace, dedicated cardio-oncology evaluation.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1019-1026"},"PeriodicalIF":2.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shear wave elastography as a screening modality for liver fibrosis in a comprehensive sickle cell disease clinic. 横波弹性成像在镰状细胞病综合门诊肝纤维化筛查中的应用。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-21 DOI: 10.1080/17474086.2026.2721482

Marissa Solow, Anas Samman, Dawn Goodyear, Natalia Rydz, Kelsey Uminski

{"title":"Shear wave elastography as a screening modality for liver fibrosis in a comprehensive sickle cell disease clinic.","authors":"Marissa Solow, Anas Samman, Dawn Goodyear, Natalia Rydz, Kelsey Uminski","doi":"10.1080/17474086.2026.2721482","DOIUrl":"https://doi.org/10.1080/17474086.2026.2721482","url":null,"abstract":"Background: Sickle cell disease (SCD) is associated with hepatobiliary complications including liver fibrosis and cirrhosis, driven by chronic hemolysis, intrahepatic sickling, and transfusion-related iron overload. Standardized screening strategies for liver fibrosis in SCD are lacking. Shear wave elastography (SWE) is a noninvasive ultrasound-based technique that measures liver stiffness and may provide an accessible tool for fibrosis assessment. The objective is to determine the proportion of adults with SCD with liver fibrosis detected using SWE and to explore associated clinical and laboratory characteristics.Research design and methods: We conducted a retrospective cohort study of adults with SCD who underwent routine outpatient SWE between 2021 and 2025. Findings were categorized using METAVIR-equivalent stages (F0-F4), with ≥F2 defined as clinically significant fibrosis. Clinical, laboratory, and imaging data within six months were collected.Results: Of 219 eligible patients, 153 (70%) underwent SWE. Median age was 35.0 years and 59% were female. Most (92%) had no or mild fibrosis, while 12 (8%) had SWE-defined clinically significant fibrosis. Abnormal SWE was associated with higher bilirubin, gamma-glutamyl transferase, and ferritin. Hepatology consultation occurred in seven patients; three required iron chelation.Conclusions: SWE-defined fibrosis was identified in 8% of patients, and may provide a feasible noninvasive approach for identifying previously unrecognized hepatic involvement.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of older adults with newly diagnosed FLT3-mutated AML: focus on lower-intensity triplet regimens. 老年人新诊断的flt3突变AML的治疗：专注于低强度的三联方案

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-18 DOI: 10.1080/17474086.2026.2720126

Sankalp Arora, Naval Daver, Farhad Ravandi, Nicholas J Short

{"title":"Treatment of older adults with newly diagnosed FLT3-mutated AML: focus on lower-intensity triplet regimens.","authors":"Sankalp Arora, Naval Daver, Farhad Ravandi, Nicholas J Short","doi":"10.1080/17474086.2026.2720126","DOIUrl":"https://doi.org/10.1080/17474086.2026.2720126","url":null,"abstract":"Introduction: Treatment options for older adults with FLT3-mutated AML who are unfit for intensive chemotherapy have evolved substantially. The combination of hypomethylating agent (HMA) and venetoclax is the current standard-of-care regimen for these patients, though outcomes remain suboptimal, particularly in FLT3-ITD mutated AML. More recently, encouraging data have emerged supporting the safety and efficacy of frontline HMA + venetoclax + FLT3 inhibitor 'triplet' regimens.Areas covered: We summarize the available evidence for different frontline treatment approaches in older adults with FLT3-mutated AML. We also discuss key practical considerations for the use of triplet regimens and provide recommendations to optimize drug doses and durations and improve tolerability. Relevant literature search was carried out using PubMed/MEDLINE databases through June 2026.Expert opinion: The HMA + venetoclax + FLT3 inhibitor triplet regimens, when administered with appropriate dose optimization and supportive care, can be delivered safely, with very high response rates and improved long-term survival in older adults with FLT3-mutated AML, positioning them as a potential new standard-of-care option. However, randomized controlled trial data are still awaited, and their safe administration requires close monitoring, robust supportive care and expertise that is most readily available at specialized academic centers.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review. 美国真性红细胞增多症患者的血栓栓塞负担、疾病进展和放血：一项系统的文献综述。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-06-11 DOI: 10.1080/17474086.2026.2683032

Naveen Pemmaraju, Qi Fan, Sarah Ronnebaum, Salima Punja, Joanna Kamar, Dasha Cherepanov, Luis Hernandez, Kristen Pettit

{"title":"Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review.","authors":"Naveen Pemmaraju, Qi Fan, Sarah Ronnebaum, Salima Punja, Joanna Kamar, Dasha Cherepanov, Luis Hernandez, Kristen Pettit","doi":"10.1080/17474086.2026.2683032","DOIUrl":"10.1080/17474086.2026.2683032","url":null,"abstract":"Introduction: Patients with polycythemia vera (PV) can experience thromboembolism (TE) and progress to myelofibrosis, acute myeloid leukemia, or myelodysplastic syndromes. Treatments for PV, particularly phlebotomy, may be burdensome and reduce patient quality of life and productivity. A systematic review was conducted to characterize the burden of TEs, disease progression, and phlebotomy among PV patients in the United States.Methods: Embase, MEDLINE and MEDLINE In-Process, PsycInfo, Cochrane Database of Systematic Reviews, and conference proceedings were searched for relevant studies published from 2014 (2023 for conference abstracts) through June 2025. Evidence was synthesized narratively.Results: Thirty-five unique studies were identified. Patients with PV experienced 1.4 to 6.5 TEs per 100 patients per year; likely risk factors for TEs included prior TEs and elevated hematocrit or hemoglobin levels. PV patients with TEs experienced higher patient healthcare costs, resource utilization, and mortality risk compared with PV patients without TEs. Disease progression was most often due to myelofibrosis (2.3%-19.9% of patients). Treatment with phlebotomy was linked with reduced quality of life and lost productivity.Conclusions: Some patients with PV may experience a substantial burden, including risk of TEs, impacts to quality of life and productivity, and disease progression, despite treatment with the current standard of care.Registration: This systematic review was prospectively registered with PROSPERO (CRD420251078378), with the authors confirming that only pilot work took place before any data collection occurred (including searching, screening, or data extraction).","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"937-955"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving salvage regimens prior to autologous stem cell transplantation in relapsed/refractory Hodgkin's lymphoma patients: updates in the novel therapy era. 改善复发/难治性霍奇金淋巴瘤患者自体干细胞移植前的挽救方案：新疗法时代的最新进展

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-06-07 DOI: 10.1080/17474086.2026.2683036

Jowon Laura Kim, Ivana N Micallef

{"title":"Improving salvage regimens prior to autologous stem cell transplantation in relapsed/refractory Hodgkin's lymphoma patients: updates in the novel therapy era.","authors":"Jowon Laura Kim, Ivana N Micallef","doi":"10.1080/17474086.2026.2683036","DOIUrl":"10.1080/17474086.2026.2683036","url":null,"abstract":"Introduction: Relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) has historically been managed with multiagent salvage chemotherapy followed by autologous stem cell transplantation (ASCT). Recently, brentuximab vedotin (BV) and programmed cell death protein 1 (PD-1) inhibitors in the salvage setting have substantially improved response rates and post-transplant outcomes. A PubMed search was conducted to identify key studies evaluating salvage therapies in R/R transplant-eligible cHL.Areas covered: This review summarizes conventional salvage regimens and modern BV/ PD-1 inhibitor-based strategies, including response-adapted approaches. Emerging data on chemotherapy-sparing regimens, retreatment after frontline PD-1 inhibitor exposure, and novel consolidation strategies are discussed. The evolving role of post-ASCT maintenance, circulating tumor DNA-guided response assessment, potential for ASCT omission in deep molecular remission, and the next generation of immunotherapeutic approaches for multiply relapsed disease are also reviewed.Expert opinion: PD-1 inhibitor-based salvage regimens now represent the preferred strategy for many transplant-eligible patients, producing unprecedented complete response rates and durable disease control after ASCT. The next major advance will be biologically guided risk stratification using metabolic and molecular response measures to individualize consolidation and potentially omit ASCT in selected patients. Novel immune-based therapies are urgently needed for patients who relapse after BV and PD-1 inhibitor therapy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"859-880"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders. 呼吁在遗传性出血性毛细血管扩张和其他慢性出血性疾病中使用复合血液学测量。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-06-08 DOI: 10.1080/17474086.2026.2686409

Hanny Al-Samkari, Raj S Kasthuri, Jenny Y Zhou, Layla N Van Doren, Keith R McCrae, Allyson M Pishko, Adrienne Hammill, Magdalena Lewandowska, Quentin Van Thillo, Ibrahim Ibrahim, Kenneth S Cohen, Bryan Sisk, Diana M Byrnes, Senthil Sukumar, Patrick Foy, Bethany T Samuelson Bannow

{"title":"A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders.","authors":"Hanny Al-Samkari, Raj S Kasthuri, Jenny Y Zhou, Layla N Van Doren, Keith R McCrae, Allyson M Pishko, Adrienne Hammill, Magdalena Lewandowska, Quentin Van Thillo, Ibrahim Ibrahim, Kenneth S Cohen, Bryan Sisk, Diana M Byrnes, Senthil Sukumar, Patrick Foy, Bethany T Samuelson Bannow","doi":"10.1080/17474086.2026.2686409","DOIUrl":"10.1080/17474086.2026.2686409","url":null,"abstract":"Introduction: Therapeutic development in hereditary hemorrhagic telangiectasia (HHT), the second-most-common inherited bleeding disorder, is rapidly accelerating. Therefore, modern clinical trials in HHT must be equipped with rigorous, fit-for-purpose hematologic endpoints.Areas covered: Due to the inadequacy of solitary hematologic measurements (hemoglobin, red cell transfusions and quantity of iron infused used as separate measurements), the recent International Consensus Report on Standardization in HHT advised widespread implementation of two composite hematologic measurements, the Hematologic Support Score and Hematologic Impact Score. The Hematologic Support Score is a composite measurement of total hematologic support (red cell transfusions and quantity of iron infused) administered over a time period, and the Hematologic Impact Score provides the total hematologic impact of an intervention, in red-cell unit equivalents, by integrating change in hemoglobin, red cell transfusions, and quantity of iron infused.Expert opinion: This article, authored by 16 hematologist-experts in HHT, hemostasis, and iron deficiency, explains these measures in depth and the importance of their implementation in clinical studies of major disorders of chronic bleeding, such as HHT, gastrointestinal angiodysplasia, and heavy menstrual bleeding. We urge clinicians, investigators, study sponsors, and regulatory bodies to adopt and promote the use of these common-sense measurements in clinical studies of chronic bleeding interventions.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"803-810"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of miR-451 target genes as prognostic markers in diffuse large B-cell lymphoma. 将 miR-451 靶基因鉴定为弥漫大 B 细胞淋巴瘤的预后标志物。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2024-11-04 DOI: 10.1080/17474086.2024.2422019

Yi Zhang, Zichen Wei, Han Xu, Xin Wang, Ting Gu, Hongliang Dong, Hongzhuan Chang, Lei Pang

{"title":"Identification of miR-451 target genes as prognostic markers in diffuse large B-cell lymphoma.","authors":"Yi Zhang, Zichen Wei, Han Xu, Xin Wang, Ting Gu, Hongliang Dong, Hongzhuan Chang, Lei Pang","doi":"10.1080/17474086.2024.2422019","DOIUrl":"10.1080/17474086.2024.2422019","url":null,"abstract":"Background: B-cell lymphoma, a diverse malignancy, is intricately regulated by multiple factors. MicroRNAs (miRNAs) have been demonstrated to be important regulators of the initiation and progression of human B-cell lymphoma, but their functions need to be further explored.Research design and methods: Two B-cell lymphoma cell lines, Romas and HBL-1, were engineered to overexpress miR-451, with cell proliferation assessed via cell counting assays. Flow cytometry was used to study the effects of miR-451 on cell cycle and apoptosis. Bioinformatics analyses were performed using GEO datasets (GSE181063, GSE32918, GSE56315) to identify DEGs, and potential miR-451 target genes were predicted using tools like ENCORI, TargetScan, and R packages. A risk model for DLBCL prognosis was developed using Cox and LASSO regression. qRT-PCR validated the expression of these target genes.Results: This study revealed that miR-451 inhibited cell proliferation, arrested the cell cycle, and induced apoptosis in human DLBCL cell lines. Bioinformatics analysis identified 9 target genes (MMP9, AQP9, RIN2, EOMES, LCP2, SELPLG, MAL, SOCS5, S1PR3) significantly associated with DLBCL prognosis, suggesting a potential mechanism by which miR-451 suppresses DLBCL development.Conclusions: Our study indicates that a specific set of miR-451 target genes may significantly influence DLBCL patient outcomes.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"975-986"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis. 靶向治疗时代的原发性弥漫性大b细胞淋巴瘤：发病率、第二原发恶性和预后。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-05-29 DOI: 10.1080/17474086.2026.2680141

Jing Wang, Dongming Zhou, Chenglan Lv, Min Zhou, Rongfu Zhou, Yuan Wan

{"title":"Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis.","authors":"Jing Wang, Dongming Zhou, Chenglan Lv, Min Zhou, Rongfu Zhou, Yuan Wan","doi":"10.1080/17474086.2026.2680141","DOIUrl":"10.1080/17474086.2026.2680141","url":null,"abstract":"Background: To comprehensively illustrate the status of primary diffuse large B-cell lymphoma (DLBCL) in the era of targeted therapies.Research design and methods: Data from patients who were newly diagnosed with primary DLBCL from 2000 to 2021 in SEER 17 Registry Database were analyzed. The incidence and occurrence of second primary malignancies (SPM) and the prognosis of DLBCL were identified.Results: A total of 106,501 DLBCL patients were included. The median age at diagnosis was 66.0 years, and the disease was more prevalent in male and white patients. The age-standardized incidence rate in 2021 was 5.6 per 100,000, showing a significant decrease (average annual percent change of -0.43%) from 2002 to 2021. The risk of developing any SPM among DLBCL survivors was approximately 30% higher than that in the general population (95% confidence interval (CI): 1.28-1.33, p < 0.05). Significant risk factors for SPMs included the male sex (hazard ratio (HR) = 1.21, 95% CI: 1.16-1.27) and a diagnosis after 2009 (HR = 1.25, 95% CI: 1.20-1.31).Conclusions: The incidence of DLBCL has slightly decreased, whereas the risk of SPM has increased. The prognosis has improved, likely because of targeted therapies. Further investigation is warranted to refine treatment strategies and reduce the SPM risk.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"957-965"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression and prognostic value of cytotoxic T-lymphocyte-associated 4 protein in classic Hodgkin lymphoma. 细胞毒性t淋巴细胞相关蛋白4在经典霍奇金淋巴瘤中的表达及预后价值。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-05-27 DOI: 10.1080/17474086.2026.2680139

Taha Koray Sahin, Hande Nur Gungor, Esin Gezmis, Ezgi Aysu Sahin, Ibrahim Barista, Arzu Saglam, Serkan Akin

{"title":"Expression and prognostic value of cytotoxic T-lymphocyte-associated 4 protein in classic Hodgkin lymphoma.","authors":"Taha Koray Sahin, Hande Nur Gungor, Esin Gezmis, Ezgi Aysu Sahin, Ibrahim Barista, Arzu Saglam, Serkan Akin","doi":"10.1080/17474086.2026.2680139","DOIUrl":"10.1080/17474086.2026.2680139","url":null,"abstract":"Background: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key inhibitory immune checkpoint expressed predominantly on activated and regulatory T cells. Although immune evasion mechanisms are central to the pathobiology of classic Hodgkin lymphoma (cHL), the prognostic significance of CTLA-4 expression remains insufficiently defined. This study aimed to evaluate the association between CTLA-4 expression, clinicopathologic characteristics, and survival outcomes in patients with cHL who received ABVD as first-line therapy.Research design and methods: This retrospective single-center study included 77 adult patients with cHL treated with ABVD as first-line therapy. CTLA-4 expression was assessed by immunohistochemistry in diagnostic biopsy specimens and categorized as negative (<10%), low (10-50%), or high (>50%).Results: High CTLA-4 expression was significantly associated with younger age, female sex, mixed cellularity histology, and advanced-stage disease (all p < 0.05). High CTLA-4 expression was associated with significantly inferior recurrence-free survival (RFS) and overall survival (OS) compared with lower expression levels.Conclusions: CTLA-4 expression represents a clinically relevant biomarker associated with adverse disease characteristics and poorer survival in cHL. Routine assessment of CTLA-4 may enhance risk stratification and help identify patients who could benefit from intensified monitoring or novel immunotherapeutic strategies.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"967-973"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy. 用CAR-T疗法治疗血液恶性肿瘤时细胞因子释放综合征的管理。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-06-10 DOI: 10.1080/17474086.2026.2684519

Ana Alarcon Tomas, Alicia Segura, Julio Chavez

{"title":"Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy.","authors":"Ana Alarcon Tomas, Alicia Segura, Julio Chavez","doi":"10.1080/17474086.2026.2684519","DOIUrl":"10.1080/17474086.2026.2684519","url":null,"abstract":"Introduction: Cytokine release syndrome (CRS) is a potentially life-threatening toxicity associated with chimeric antigen receptor (CAR)-T cell therapy, particularly in hematological malignancies. As CAR-T therapies are increasingly integrated into clinical practice, managing CRS effectively is critical to maximizing therapeutic benefit while minimizing harm.Areas covered: This review provides a comprehensive overview of CRS in the context of CAR-T therapy for hematologic cancers. It outlines the current definitions and grading systems, highlights key aspects of CRS pathophysiology, and analyzes the incidence and severity of CRS across pivotal clinical trials in large B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma. Standard management approaches, including anti-cytokine therapies and corticosteroids, are discussed alongside emerging strategies such as early intervention and prophylaxis using anakinra and corticosteroids. The review is informed by a structured evaluation of clinical studies and real-world data, reflecting evolving treatment paradigms.Expert opinion: CRS remains a major challenge, therefore early recognition, standardized grading, and targeted intervention will improve outcomes. Future efforts should focus on predictive biomarkers, personalized prophylaxis, and next-generation CAR constructs to reduce toxicity. The real-world experience mirrors trial data, reinforcing the reproducibility and scalability of these evolving management strategies.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"881-892"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0